AIM: To observe the therapeutic effects of different dosage regimens of conbercept on clinical significant diabetic macular edema(CSME).

METHODS: Totally 65 patients with diabetes and CSME who were admitted to the Ophthalmology Department at Ganzhou People's Hospital between January 2019 and January 2020 were selected as the research subjects, and divided into observation group(n=33, conbercept 5+PRN regimen)and control group(n=32, conbercept 3+PRN regimen)using random number table method. Visual acuity test and optical coherence tomography(OCT)were carried out at 1, 2, 3, 6, 9, 12mo after treatment. Changes in the best corrected visual acuity(BCVA,LogMAR)and central macular thickness(CMT)were compared between the two groups. The mean injection times and complications in the two groups were recorded.

RESULTS: The BCVA was improved and CMT thinned in the two groups at 1, 2, 3, 6, 9, 12mo after treatment(P<0.05). There was no statistically significant difference in BCVA and CMT between the two groups before treatment, and at 1, 2, 3, 6, 9, 12mo after treatment(P>0.05). The mean injection times in observation group was more than that in the control group \〖(5.81±0.54)times vs (4.19±0.41)times\〗(P<0.05). In the early stage of postoperative follow-up, there were 30 times(23%)and 15 times(22%)of subconjunctival hemorrhage in observation group and control group, respectively(P>0.05). No other severe complications were observed in the two groups.

CONCLUSION:Both conbercept 3+PRN and conbercept 5+PRN are effective in the treatment of patients with diabetes and CSME. Both can significantly improve the patients' visual acuity and reduce CMT, with equivalent effect. The latter may increase the injection times but its adverse reactions are tolerable. In addition, it is safe and reliable.